To amend the reporting requirements for the SBIR and STTR programs, and for other purpose.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill requires federal agencies to send SBIR/STTR program annual reports to Congressional small business committees and publish reports on agency websites, enhancing transparency and legislative oversight, mandates GAO study on SBIR/STTR program effectiveness regarding participant diversification (new entrants, women-owned, minority-owned businesses) and technology commercialization outcomes, and requires extends SBIR/STTR award timeliness reporting requirement from 3 to 11 years and adds metrics tracking average and median agency review times for program proposals. It relies on reporting requirements and grants. The main policy areas are Small Business, Finance, Science & Space, and Trade.
Who Benefits and How
Small business concerns seeking NIH SBIR/STTR funding could gain revenue opportunities, Congressional small business committees would be affected, and Biotech and life sciences startups could gain revenue opportunities.
Who Bears the Burden and How
Federal agencies with SBIR/STTR programs would take on compliance duties, Government Accountability Office would take on compliance duties, and National Institutes of Health would take on compliance duties.
Key Provisions
- Requires federal agencies to send SBIR/STTR program annual reports to Congressional small business committees and publish reports on agency websites, enhancing transparency and legislative oversight.
- Mandates GAO study on SBIR/STTR program effectiveness regarding participant diversification (new entrants, women-owned, minority-owned businesses) and technology commercialization outcomes.
- Requires extends SBIR/STTR award timeliness reporting requirement from 3 to 11 years and adds metrics tracking average and median agency review times for program proposals.
- Creates NIH pilot program to accelerate SBIR/STTR award timelines with simplified procedures, targeting 90-day funding release and allowing flexible peer review approaches, terminating September 30, 2030.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill requires federal agencies to send SBIR/STTR program annual reports to Congressional small business committees and publish reports on agency websites, enhancing transparency and legislative oversight, mandates GAO study on SBIR/STTR program effectiveness regarding participant diversification (new entrants, women-owned, minority-owned businesses) and technology commercialization outcomes, and requires extends SBIR/STTR award timeliness reporting requirement from 3 to 11 years and adds metrics tracking average and median agency review times for program proposals.
Key Policy Areas
Small Business, Finance, Science & Space, Trade
Primary Purpose
The bill requires federal agencies to send SBIR/STTR program annual reports to Congressional small business committees and publish reports on agency websites, enhancing transparency and legislative oversight, mandates GAO study on SBIR/STTR program effectiveness regarding participant diversification (new entrants, women-owned, minority-owned businesses) and technology commercialization outcomes, and requires extends SBIR/STTR award timeliness reporting requirement from 3 to 11 years and adds metrics tracking average and median agency review times for program proposals.
Policy Domains
SBIR/STTR Oversight Act
Identified Gains
- Small business concerns seeking NIH SBIR/STTR funding
- Congressional small business committees
- Biotech and life sciences startups
- Women-owned small business concerns
- Minority-owned small business concerns
Identified Costs
- Federal agencies with SBIR/STTR programs
- Government Accountability Office
- National Institutes of Health
Legislative Progress
IntroducedMr. McGarvey introduced the following bill; which was referred to …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Congressional small business committees, Federal agencies with SBIR/STTR programs, Government Accountability Office
Positive-direction: Congressional small business committees
Negative-direction: Federal agencies with SBIR/STTR programs, Government Accountability Office, National Institutes of Health
Minority-owned small business concerns, Small business concerns applying for SBIR/STTR awards, Small business concerns participating in SBIR/STTR
Small business concerns seeking NIH SBIR/STTR funding
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_director"
- → Director of the National Institutes of Health
- "comptroller_general"
- → Comptroller General of the United States
Key Definitions
Terms defined in this bill
A small business concern that has not previously received an SBIR or STTR award
Small business concerns located in States with historically low SBIR/STTR awards, small business concerns owned and controlled by women, and small business concerns owned and controlled by socially and economically disadvantaged individuals
A Federal agency carrying out an SBIR or STTR program under section 9 of the Small Business Act
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology